Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fulranumab monotherapy for osteoarthritis of the hip or knee
NL-OMON42211Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Dec 2015
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of fulranumab in osteoarthritis (OA) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline to Week 16 in WOMAC pain subscale score, Change from baseline to Week 16 in WOMAC physical function subscale score and 1 more. Started Dec 2015; status: active, not recruiting.
02
Drugs
fulranumab
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NL-OMON42211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42211.